THS-SX-C

Description

Choose from a high efficiency cutter model that can tackle calcified plaque or a smooth cutter model that can treat mild-to-moderately calcified lesions. TurboHawk™ is proven clinically in the landmark DEFINITIVE LE trial, the study found that diabetic PAD patients fared as well as nondiabetics and that claudicants had high patency at 12 months when treated with plaque excision technology.¹

The TurboHawk™ peripheral plaque excision system is intended for use in the atherectomy of the peripheral vasculature. The TurboHawk™ catheter is not intended for use in the coronary, carotid, iliac, or renal vasculature.

The TurboHawk™ catheter is indicated for use in conjunction with the SpiderFX™ embolic protection device in the treatment of severely calcified lesions (LS-C and LX-C only).

McKinsey JF, Zeller T, Rocha-Singh KJ, Jaff MR, Garcia LA; DEFINITIVE LE Investigators. Lower extremity revascularization using directional atherectomy: 12-month prospective results of the DEFINITIVE LE study. JACC Cardiovasc Interv. 2014;7(8):923–33.

Not what you're looking for?

Find more information, including other available configurations, for TurboHawk™ peripheral plaque excision system.

First Name

Last Name

Hospital Or Organization

Job Role

Specialty

Confirm country/region

Just to confirm, is this the product or product type that interests you?

{{productNamePlaceholder}}

Confirm country/region

Before we get started, what best describes you?

Confirm country/region

Before we get started, what best describes you?

First Name

Last Name

Hospital Or Organization

HOSPITAL POSTAL CODE

Job Role

Specialty

First Name

Last Name

PHONE

Hospital Or Organization

HOSPITAL POSTAL CODE

Job Role

Specialty

Description

Not what you're looking for?

United States

Customer Care Team